Elion Therapeutics Raises $81M for Advancement of Antifungal Treatment

Elion Therapeutics raises $81M in Series B Funding

Elion Therapeutics, a leader in the treatment of life-threatening invasive fungal infections (IFIs), has secured $81 million in Series B funding. With a focus on advancing their polyene antifungal SF001, Elion Therapeutics is seeking partnerships with healthcare providers, pharmaceutical companies, and research institutions to further develop and commercialize innovative antifungal therapies.

Funding Amount: $81 million

Industry: Online Audio and Video Media

Employee Count: 11-50

CEO: Jeff Lawson (CEO Linkedin)

What Elion Therapeutics needs to buy: Elion Therapeutics is looking for collaborations with clinical research organizations, manufacturers, suppliers, and regulatory experts to advance their antifungal therapies, ensure efficient production and distribution, and navigate the regulatory landscape for successful commercialization.